BFH772 (VEGFR2 inhibitor): Technical Guidance and Best Practices

What This Product Solves

BFH772 is a potent small-molecule VEGFR2 inhibitor specifically engineered to modulate VEGFR2-mediated signaling pathways with high selectivity. This compound addresses the need for targeted suppression of VEGFR2-driven angiogenesis in research workflows, particularly for studies involving tumor angiogenesis and in vivo tumor growth inhibition. Its narrow selectivity profile and significant potency (IC₅₀ = 3 nM for VEGFR2) enable researchers to isolate the role of VEGFR2 in angiogenic processes without substantially affecting related kinases or broader signaling networks (source: product_spec).

BFH772 is not appropriate for protocols that require broad-spectrum kinase inhibition or water-soluble VEGFR2 inhibitors. Instead, it is optimized for models and assays that demand high specificity, particularly when organic solvent compatibility is feasible and when downstream effects of off-target kinase inhibition must be minimized (source: internal_article).

Protocol Parameters

• Kinase Inhibition Assay | IC₅₀ = 3 nM | In vitro enzyme assays targeting VEGFR2 | Demonstrates high-affinity inhibition of VEGFR2 kinase activity, enabling precise modulation in signaling studies | product_spec
• Solubility in DMSO | ≥53.4 mg/mL | Compound preparation for cell-based and biochemical assays | High solubility in DMSO allows for concentrated stock solutions suitable for organic solvent-compatible protocols | product_spec
• Storage Temperature | -20°C | Compound storage for long-term integrity | Maintains chemical stability and prevents degradation prior to use | product_spec
• Solubility in Ethanol | ≥15.33 mg/mL | Alternative solvent for assay preparation | Useful for workflows or formulations requiring ethanol as a solvent | product_spec
• In Vivo Administration | Oral (dose user-optimized) | Animal tumor models for angiogenesis research | Oral bioavailability supports use in murine or other in vivo models for tumor growth and angiogenesis studies | workflow_recommendation

Workflow Setup and QC Checklist

• Compound Preparation: Dissolve BFH772 in DMSO or ethanol to prepare concentrated stock solutions. Confirm clarity and absence of precipitate prior to dilution. Avoid water, as compound is insoluble and may precipitate, reducing assay reliability (source: internal_article).
• Aliquoting and Storage: Aliquot stock solutions to minimize freeze-thaw cycles. Store at -20°C and avoid long-term storage of diluted solutions to maintain activity and purity.
• Vehicle Controls: Always match DMSO or ethanol content in control wells to experimental conditions to account for solvent effects.
• Purity Verification: Use only BFH772 vials accompanied by certificates of analysis confirming purity >96%.
• Quality Control Data Review: Examine accompanying QC and safety documents from the supplier for every lot used.

Common Failure Modes and Fixes

• Precipitation in Assay Media: If BFH772 precipitates after dilution, verify that stock was fully dissolved and avoid exceeding recommended DMSO/ethanol concentrations in final working solutions. Pre-warm solvents if necessary for complete dissolution.
• Reduced Inhibitory Activity: Loss of potency may result from improper storage (e.g., repeated freeze-thaw cycles or prolonged storage at higher temperatures). Use freshly prepared aliquots and store at -20°C as specified.
• Off-Target Effects: If unexpected cellular responses occur, confirm that experimental design does not require broad kinase inhibition—BFH772 is highly selective for VEGFR2 and shows greatly reduced activity against other kinases (source: internal_article).
• Solvent Toxicity: DMSO or ethanol above 0.1-0.5% v/v in cell-based assays may affect cell viability. Titrate vehicle concentration and include vehicle-only controls in all experiments.

Scope and Limitations

• Water Insolubility: BFH772 is not suitable for experiments or delivery methods requiring aqueous solubility. For such workflows, alternative compounds must be considered.
• Narrow Selectivity Profile: This inhibitor should not be used where broad-spectrum kinase inhibition is required, as its activity is highly selective for VEGFR2 with minimal cross-reactivity (source: product_spec).
• Long-Term Solution Stability: Storage of diluted solutions, even at -20°C, is not recommended due to potential degradation affecting reproducibility.
• In Vivo Use: Oral administration is supported for animal tumor models, but dose and formulation should be optimized for each protocol. Clinical data referenced in the product dossier pertain to rosacea but are not a basis for research use outside preclinical workflows.

Conclusion

BFH772 (VEGFR2 inhibitor) is a rigorously characterized, small-molecule VEGFR2 signaling pathway inhibitor designed for workflows requiring precise and selective modulation of angiogenesis, particularly in tumor model systems. Its high selectivity and compatibility with DMSO/ethanol make it suitable for both in vitro and in vivo research when proper protocol parameters and handling practices are observed. For further technical guidance and detailed protocol recommendations, consult the BFH772 (VEGFR2 inhibitor) product page and supporting internal articles. APExBIO supplies this compound with full QC documentation to ensure reproducibility in research applications.